Otonomy Company Profile (NASDAQ:OTIC)

About Otonomy

Otonomy logoOtonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company's product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OTIC
  • CUSIP:
Key Metrics:
  • Previous Close: $15.55
  • 50 Day Moving Average: $15.26
  • 200 Day Moving Average: $16.50
  • 52-Week Range: $10.50 - $19.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.67
  • P/E Growth: -0.19
  • Market Cap: $469.52M
  • Outstanding Shares: 30,194,000
  • Beta: 2.91
Profitability:
  • Return on Equity: -46.65%
  • Return on Assets: -44.40%
Debt:
  • Current Ratio: 17.58%
  • Quick Ratio: 17.44%
Additional Links:
Companies Related to Otonomy:

Analyst Ratings

Consensus Ratings for Otonomy (NASDAQ:OTIC) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.50 (96.14% upside)

Analysts' Ratings History for Otonomy (NASDAQ:OTIC)
Show:
DateFirmActionRatingPrice TargetDetails
11/2/2016Piper Jaffray CompaniesReiterated RatingBuy$32.00View Rating Details
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00View Rating Details
10/9/2015Bank of America CorpUpgradeNeutral -> Buy$31.00View Rating Details
8/13/2015J P Morgan Chase & CoInitiated CoverageHold$30.00View Rating Details
8/10/2015Sanford C. BernsteinUpgradeMarket Perform -> Outperform$30.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Otonomy (NASDAQ:OTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Otonomy (NASDAQ:OTIC)
Current Year EPS Consensus Estimate: $-3.75 EPS
Next Year EPS Consensus Estimate: $-3.33 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.79)($0.79)($0.79)
Q2 20161($0.92)($0.92)($0.92)
Q3 20161($0.93)($0.93)($0.93)
Q4 20161($1.04)($1.04)($1.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Otonomy (NASDAQ:OTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Otonomy (NASDAQ:OTIC)
Insider Ownership Percentage: 17.90%
Institutional Ownership Percentage: 83.55%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2016Carl LebelInsiderSell10,625$18.07$191,993.75View SEC Filing  
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.00View SEC Filing  
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.00View SEC Filing  
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.00View SEC Filing  
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.00View SEC Filing  
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.00View SEC Filing  
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.56View SEC Filing  
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20View SEC Filing  
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60View SEC Filing  
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.00View SEC Filing  
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20View SEC Filing  
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.00View SEC Filing  
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Otonomy (NASDAQ:OTIC)
DateHeadline
News IconOtonomy Inc OTIC Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:OTIC)
www.bioportfolio.com - February 27 at 5:39 PM
News IconSell-side Consensus Sees Otonomy, Inc. (NASDAQ:OTIC) Going Where Near-Term? - Aiken Advocate (NASDAQ:OTIC)
aikenadvocate.com - February 24 at 8:10 PM
News IconStock Watch for Otonomy, Inc. (NASDAQ:OTIC) - Midway Monitor (NASDAQ:OTIC)
midwaymonitor.com - February 24 at 8:10 PM
globenewswire.com logoOtonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update - GlobeNewswire (press release) (NASDAQ:OTIC)
globenewswire.com - February 24 at 8:10 PM
feeds.benzinga.com logoOtonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update (NASDAQ:OTIC)
feeds.benzinga.com - February 24 at 8:12 AM
News IconAre Analysts Optimistic About Where Otonomy, Inc. (NASDAQ:OTIC) is Heading? - Winfield Review (NASDAQ:OTIC)
winfieldreview.com - February 22 at 7:12 PM
investornewswire.com logoStrong Sell Recommendations Of Otonomy, Inc. (NASDAQ:OTIC) At 0 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - February 21 at 5:48 PM
News IconAnalysts Peer Into Their Crystal Balls For Otonomy, Inc. (NASDAQ:OTIC): Where Is It headed? - Winfield Review (NASDAQ:OTIC)
winfieldreview.com - February 21 at 5:48 PM
News IconStock Perspective: Otonomy, Inc. (NASDAQ:OTIC) Company Earnings Watch - Aiken Advocate (NASDAQ:OTIC)
aikenadvocate.com - February 19 at 9:32 AM
News IconMarket Sheet: Watching the Levels for Otonomy, Inc. (NASDAQ:OTIC) - Sherwood Daily (NASDAQ:OTIC)
sherwooddaily.com - February 16 at 11:41 PM
News IconMarket Sheet: Watching the Levels for Otonomy, Inc. (NASDAQ:OTIC) - Sherwood Daily (NASDAQ:OTIC)
sherwooddaily.com - February 16 at 11:41 PM
News IconHere's Who Just Picked Up Otonomy Inc. (NASDAQ:OTIC) Shares - Small Cap Exclusive (press release) (NASDAQ:OTIC)
smallcapexclusive.com - February 16 at 11:41 PM
News IconHere's Who Just Picked Up Otonomy Inc. (NASDAQ:OTIC) Shares - Small Cap Exclusive (press release) (NASDAQ:OTIC)
smallcapexclusive.com - February 16 at 11:41 PM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) EPS Target Set At $-0.56 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - February 3 at 7:54 PM
News IconLooking at Moving Averages for Otonomy Inc. (OTIC) - Market Point (NASDAQ:OTIC)
mtptnews.com - January 30 at 7:45 PM
News IconSell-side is Weighing in on Otonomy, Inc. (NASDAQ:OTIC) Earnings - Aiken Advocate (NASDAQ:OTIC)
aikenadvocate.com - January 30 at 12:35 AM
News IconStock Perspective: Otonomy, Inc. (NASDAQ:OTIC) Earnings in View - Aiken Advocate (NASDAQ:OTIC)
aikenadvocate.com - January 28 at 5:32 AM
News IconEarnings in Full Force, Analysts Take Aim at Otonomy, Inc. (NASDAQ:OTIC) - Wall Street Beacon (NASDAQ:OTIC)
wsbeacon.com - January 27 at 12:22 AM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Otonomy, Inc. (NASDAQ:OTIC) - Prospect Journal (NASDAQ:OTIC)
prospectjournal.com - January 24 at 12:26 AM
News IconStock Update on Earnings & Estimates for Otonomy, Inc. (NASDAQ:OTIC) - Aiken Advocate (NASDAQ:OTIC)
aikenadvocate.com - January 20 at 7:54 PM
finance.yahoo.com logoOtonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss (NASDAQ:OTIC)
finance.yahoo.com - January 19 at 11:43 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Otonomy, Inc. (NASDAQ:OTIC) - Prospect Journal (NASDAQ:OTIC)
prospectjournal.com - January 17 at 11:15 AM
biz.yahoo.com logoOTONOMY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:OTIC)
biz.yahoo.com - January 13 at 11:58 PM
4-traders.com logoThe Three Most Important Questions For TESARO Inc (NASDAQ:TSRO) Shareholders Right Now (NASDAQ:OTIC)
www.4-traders.com - January 13 at 5:50 AM
News IconOtonomy Inc OTIC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OTIC)
www.bioportfolio.com - January 13 at 5:50 AM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - January 12 at 7:44 PM
News IconStock Getting Tripped Up In Session: Otonomy, Inc. (NASDAQ:OTIC) - Wall Street Beacon (NASDAQ:OTIC)
wsbeacon.com - January 12 at 5:45 AM
News IconGrowth Story Unfolding for Otonomy, Inc. (NASDAQ:OTIC) - Prospect Journal (NASDAQ:OTIC)
prospectjournal.com - January 10 at 8:37 AM
News IconOtonomy phase 3 trial of Otiprio in patients with acute otitis externa meets primary endpoint - pharmabiz.com (NASDAQ:OTIC)
www.pharmabiz.com - January 10 at 8:37 AM
finance.yahoo.com logoOtonomy Provides Corporate and Product Pipeline Update (NASDAQ:OTIC)
finance.yahoo.com - January 9 at 7:45 PM
finance.yahoo.com logo7:34 am Otonomy expects 2016 Non-GAAP operating expenses to be at the low end of the $100-105 mln previous guidance range; sees 2017 non-GAAP operating expenses of $85-90 mln (NASDAQ:OTIC)
finance.yahoo.com - January 9 at 7:45 PM
News IconOtonomy phase 3 trial of Otiprio in patients with acute otitis externa meets primary endpoint (NASDAQ:OTIC)
www.pharmabiz.com - January 9 at 4:50 AM
News IconFirst Week of OTIC February 17th Options Trading (NASDAQ:OTIC)
www.stockoptionschannel.com - January 6 at 7:48 PM
capitalcube.com logoOtonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : January 6, 2017 (NASDAQ:OTIC)
www.capitalcube.com - January 6 at 7:48 PM
streetinsider.com logoOtonomy (OTIC) Says Phase 3 Clinical Trial of OTIPRIO Met Primary Endpoint (NASDAQ:OTIC)
www.streetinsider.com - January 5 at 11:50 PM
schaeffersresearch.com logoStocks On the Move: Constellation Brands, Inc., L Brands Inc, and Otonomy Inc (NASDAQ:OTIC)
www.schaeffersresearch.com - January 5 at 11:50 PM
us.rd.yahoo.com logoOtonomy's ear infection drug succeeds in late-stage trial (NASDAQ:OTIC)
us.rd.yahoo.com - January 5 at 11:50 PM
publicnow.com logoOtonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa (NASDAQ:OTIC)
us.rd.yahoo.com - January 5 at 11:50 PM
marketexclusive.com logoWhat We're Watching In Biotech For January: Otonomy Inc (NASDAQ:OTIC) and TESARO Inc (NASDAQ:TSRO) - Market Exclusive (NASDAQ:OTIC)
marketexclusive.com - January 4 at 6:24 AM
finance.yahoo.com logoOtonomy to Present at the J.P. Morgan Healthcare Conference (NASDAQ:OTIC)
finance.yahoo.com - January 3 at 10:22 AM
investornewswire.com logoSentiments And Ratings Alert: Otonomy, Inc. (NASDAQ:OTIC) - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - December 29 at 7:01 PM
realistinvestor.com logoOtonomy, Inc. (NASDAQ:OTIC) Quarterly EPS At $-0.91 - RealistInvestor.com (NASDAQ:OTIC)
www.realistinvestor.com - December 29 at 7:01 PM
News IconTop Stock With Upside & Growth Potential: Otonomy, Inc. (NASDAQ:OTIC) - Prospect Journal (NASDAQ:OTIC)
prospectjournal.com - December 27 at 9:51 AM
investornewswire.com logoOtonomy, Inc. (NASDAQ:OTIC) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:OTIC)
www.investornewswire.com - December 20 at 11:39 PM
capitalcube.com logoOtonomy, Inc. – Value Analysis (NASDAQ:OTIC) : December 19, 2016 (NASDAQ:OTIC)
www.capitalcube.com - December 20 at 1:30 PM
capitalcube.com logoOtonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : December 16, 2016 (NASDAQ:OTIC)
www.capitalcube.com - December 16 at 7:49 PM
News IconNoteworthy Thursday Option Activity: OTIC, MET, RGLD (NASDAQ:OTIC)
www.stockoptionschannel.com - December 15 at 8:04 PM
News IconVC Score In Focus for Otonomy, Inc. (NASDAQ:OTIC) - Marion Business Daily (NASDAQ:OTIC)
marionbusinessdaily.com - December 14 at 7:47 PM
News IconWatching CCI and RSI levels on Otonomy Inc. (OTIC) - StockTalk Daily (NASDAQ:OTIC)
stocktalkdaily.com - December 13 at 12:14 AM
insidermonkey.com logoHedge Funds Are Selling Otonomy Inc (OTIC) (NASDAQ:OTIC)
www.insidermonkey.com - December 12 at 7:12 PM

Social

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Where is Otonomy's stock going? Where will Otonomy's stock price be in 2017?

2 brokers have issued 12-month price objectives for Otonomy's stock. Their forecasts range from $29.00 to $32.00. On average, they anticipate Otonomy's stock price to reach $30.50 in the next twelve months.

When will Otonomy announce their earnings?

Otonomy is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

Who owns Otonomy stock?

Otonomy's stock is owned by a number of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (9.73%), Orbimed Advisors LLC (6.13%), FMR LLC (2.42%), Kingdon Capital Management L.L.C. (2.00%), State Street Corp (1.74%) and Clough Capital Partners L P (0.78%). Company insiders that own Otonomy stock include Carl Lebel, Chau Quang Khuong, David Allen Weber, Orbimed Advisors Llc, Paul E Cayer and Robert Michael Savel II.

Who sold Otonomy stock? Who is selling Otonomy stock?

Otonomy's stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Federated Investors Inc. PA, FT Options LLC and Clough Capital Partners L P.

Who bought Otonomy stock? Who is buying Otonomy stock?

Otonomy's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, Kingdon Capital Management L.L.C., Flinton Capital Management LLC, Tyers Asset Management LLC, Russell Investments Group Ltd. and FIL Ltd.

How do I buy Otonomy stock?

Shares of Otonomy can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Otonomy stock cost?

One share of Otonomy stock can currently be purchased for approximately $15.55.

Otonomy (NASDAQ:OTIC) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Otonomy (NASDAQ:OTIC)

Earnings History Chart

Earnings by Quarter for Otonomy (NASDAQ:OTIC)

Dividend History Chart

Dividend Payments by Quarter for Otonomy (NASDAQ:OTIC)

Last Updated on 2/27/2017 by MarketBeat.com Staff